|
The Multiple Sclerosis Market Will Grow 10 Percent Annually Through 2018 As …
The Providence Journal … be followed by the emergence of more-convenient reformulations of platform injectables and three highly efficacious monoclonal antibodies– Genzyme/Bayer HealthCare’s Lemtrada, Roche/Genentech’s ocrelizumab and Biogen Idec/AbbVie’s daclizumab. |
|
The Multiple Sclerosis Market Will Grow 10 Percent Annually Through 2018 As …
PR Newswire (press release) … be followed by the emergence of more-convenient reformulations of platform injectables and three highly efficacious monoclonal antibodies— Genzyme/Bayer HealthCare’s Lemtrada, Roche/Genentech’s ocrelizumab and Biogen Idec/AbbVie’s daclizumab. |
|
Biogen Idec, Inc. (BIIB) Tops Q2 EPS by 37c; Issues Solid Guidance
StreetInsider.com (subscription) … generated from underlying patient demand was approximately $110 million. RITUXAN® (rituximab) revenues from our unconsolidated joint business arrangement were $289 million for the quarter, an increase of 1% compared to the second quarter of 2012. |
AFPNew cancer drugs help drive Roche in first halfPMLiVEMabThera/ Rituxan (rituximab) for blood cancers and arthritis climbed 3 per cent to CHF 3.40bn and breast cancer stalwart Herceptin (trastuzumab) rose 5 per cent to 3.08bn Swiss francs, both benef…
|
Genentech’s Obinutuzumab (GA101) Delayed Disease Progression Longer …
DailyFinance … monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan® (rituximab … Roche antibody tops Rituxan in blood cancer CLLPMLiVE Genentech Trumpets Phase III Results for CLL CandidateGenetic Engineering News |
|
Harbour Antibodies Licenses H2L2 Mice to Pfizer
MarketWatch ROTTERDAM, the Netherlands & CAMBRIDGE, Mass., Jul 24, 2013 (BUSINESS WIRE) — Harbour Antibodies, the creator of transgenic mice to aid in the development of new human therapeutic antibodies, announced today that it has licensed its H2L2 mice, … Harbour Antibodies BV Raises ‚Ǩ2.5M ($3.3M) to Accelerate the Development …PharmiWeb.com (press release) Atlas leads €2.5m round for Harbour Antibodiesunquote news (subscription) Pfizer licenses antibody tech from Atlas-backed startup HarbourFierceBiotech |
|
Galectin Announces First Patient Dosed in Phase 1 Trial of GR-MD-02; Merck …
HispanicBusiness.com … monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan® (rituximab … |
Antibodies for Common HPV Strain Found in One-Third of Patients with …OncLiveApproximately one-third of cases of oropharyngeal cancer carried antibodies to one of the driver proteins from human papillomavirus type 16 (HPV16), and those antibodies cou…
LifeSpan BioSciences Expands IHC-Plus(TM) Product Line to More Than 10000 …4-traders (press release)SEATTLE, WA, July 24, 2013 – (eTeligis via ACCESSWIRE) – LifeSpan BioSciences, Inc. (LSBio), a leading provider of antibodies for researchers worldwid…
LifeSpan BioSciences Expands IHC-Plus(TM) Product Line to More Than 10000 …Baystreet.caSEATTLE, WA, July 24, 2013 – (eTeligis via ACCESSWIRE) – LifeSpan BioSciences, Inc. (LSBio), a leading provider of antibodies for researchers worldwide, has increa…